相关实验视频

Updated: Jun 4, 2025

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice

Published on: June 28, 2021

在急性严重胰腺炎与全身炎症反应综合征上,西维莱斯塔特的作用和安全性:一项回顾性研究

Jiafeng Xie^1,2,3, Ruyi Lei^1,2,3, Hui Pei^1,2,3

¹Department of emergency ICU, the first affiliated hospital of Zhengzhou University, Henan, 450052, China.

Scientific reports

|January 2, 2025

概括

在严重的急性胰腺炎 (SAP) 和全身炎症反应综合征 (SIRS) 中,西维莱斯塔 (SV) 治疗并没有降低死亡率,但确实缩短了呼吸机使用和重症监护室 (ICU) 停留时间.

科学领域:

临界护理医学临界护理医学
胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

严重急性胰腺炎 (SAP) 是一种危急的疾病,通常伴有全身炎症反应综合征 (SIRS).
目前使用SIRS治疗SAP的治疗方法旨在控制炎症和器官支持.
西维莱斯塔特 (SV) 是一种具有潜在抗炎作用的中性粒细胞弹性酶抑制剂.

研究的目的:

评估sivelestat (SV) 在患有严重急性胰腺炎 (SAP) 和全身炎症反应综合征 (SIRS) 的患者的疗效和安全性.
为了比较临床结果,包括死亡率,住院时间,以及机械通风的持续时间,在患者之间治疗和没有SV.

主要方法:

一项前性研究涉及102名SAP和SIRS患者,他们在紧急重症监护病房接受治疗.
患者被分为对照组 (n=56) 和 SV 组 (n=46).
两组之间的基线数据,疾病结果,住院时间,呼吸机使用和死亡率的比较.

主要成果:

控制组和SV组之间的基线数据没有显著差异.
在治疗一周后,所有测量指数在两组都得到改善.
与对照组相比,SV组的呼吸器使用时间 (p=0.0400) 和ICU停留时间 (p=0.0495) 显著缩短 (p=0.0495).
死亡率在两组之间没有显著差异.

结论:

在患有严重急性胰腺炎 (SAP) 和全身炎症反应综合征 (SIRS) 的患者中,Sivelestat (SV) 治疗没有降低死亡率.
SV显著减少了机械通风和重症监护室 (ICU) 停留时间的持续时间.
在患有SIRS的SAP患者中,SV可能是改善资源利用的有益辅助疗法.

关键词:

严重的急性胰腺炎在西维尔州.系统性炎症反应综合征

更多相关视频

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection

Published on: May 10, 2024

Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis

Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis

Published on: January 27, 2023

相关概念视频

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

Acute Pancreatitis I: Introduction

Acute Pancreatitis I: Introduction

Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...